Trials / Completed
CompletedNCT04502056
Covid-19 Messaging to Underserved Communities - 2nd Experiment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20,460 (actual)
- Sponsor
- National Bureau of Economic Research, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19. The sample will include African American and white adult Americans and oversample those with less than a college degree.
Detailed description
Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. Moreover, since our last experiment, the killing of George Floyd by Minnesota police has raised awareness of structural racism in the United States. The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19.The sample will include African American and white adult Americans and oversample those with less than a college degree.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Acknowledgement Racial Injustice AMA | Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice. |
| BEHAVIORAL | African American Sender Acknowledgement | Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA |
| BEHAVIORAL | African American Sender in Informational Videos. | Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos. |
| BEHAVIORAL | Racial Inequality Highlighted | Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts |
| BEHAVIORAL | AMA Acknowledgement Drug Pricing | Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing |
| BEHAVIORAL | White Sender in Acknowledgement | Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement |
| BEHAVIORAL | White Sender in Informational Videos | Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video |
| BEHAVIORAL | No Racial Inequality Highlighting | In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted |
| BEHAVIORAL | Placebo videos | Videos not related to covid-19 will be shown |
Timeline
- Start date
- 2020-08-07
- Primary completion
- 2020-09-06
- Completion
- 2020-09-06
- First posted
- 2020-08-06
- Last updated
- 2021-07-27
- Results posted
- 2021-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04502056. Inclusion in this directory is not an endorsement.